Estonian Biotech Icosagen Has Developed Highly Potent Next-Generation Therapeutic and Preventative Anti-SARS-CoV-2 Neutralizing Antibodies as Promising Drug Candidates for Covid-19
On
October 12, 2020, the U.S. Patent Office received and registered Icosagen Cell
Factory OÜ’s Patent Application No. 63090576 “SARS-CoV-2 Neutralizing
Antibodies."
Read more ›
KTH protein production with QMCF
KTH produced almost 1300 human secreted recombinant proteins using Icosagen’s QMCF platform within the Human Secretome project https://www.sciencedirect.com/science/article/pii/S1871678420301321
Read more ›
Icosagen's COVID-19 antibody ELISA test is available for diagnostics with an IVD CE mark
On September 3rd the Health Board registered our developed diagnostic test with the IVD CE mark. The test can be used to detect antibodies against SARS-CoV-2 in human blood samples to determine if a person has had the disease. Volunteers recovered from COVID-19, whose donated blood was used to validate the test, played a very important role in the validation of the test. Long-term studies are underway to determine the duration of antiviral immunity associated with COVID-19 and possible protection against future infections. Although the company is not developing the vaccine, these studies also provide a better understanding of the possibility of using the vaccine and the duration of the antibody immunity against SARS-CoV-2. The test is based on recombinant viral proteins produced by Icosagen and has been developed in Tartu. The test works by enzyme-linked immunosorbent assay (ELISA), allowing the semi-quantitative in vitro detection of IgG and IgM antibodies against SARS-CoV-2 virus in human serum or plasma (Medical Device Database (MSA) code 15531). All antigens used for the test are also available in our catalogue.
Read more ›
Carlova Consult supports Icosagen’s research and development against COVID-19
On 26th of august Carlova Consult, head by Andres Metspalu, donated to Icosagen 18 Thermo Scientific F1-ClipTip pipettes and a supplementary selection of pipette tips. Icosagen’s team is very thankful for the donation and will put it to good use in our mutual fight against the COVID-19 pandemic.
Read more ›
Icosagen continues to support your research
Icosagen is
fully operational, and will do everything to finish all current and upcoming
projects in time, despite of the growing COVID-19 influence all over the world.
Read more ›
Press release: Icosagen Cell Factory was awarded EUR 1.2 million
HybriFree recombinant antibody development article is published
Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.
The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST
QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California
Icosagen Cell Factory was titled the Best Entrepreneur of 2013
Icosagen Cell Factory presentation at Cell Line Development Conference